In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on Ultragenyx (RARE). The company’s shares closed yesterday at $48.38, close to its 52-week low of $41.67.
According to TipRanks.com, Kasimov is a 1-star analyst with an average return of -1.2% and a 36.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Jounce Therapeutics Inc.
Ultragenyx has an analyst consensus of Moderate Buy, with a price target consensus of $69, implying a 42.6% upside from current levels. In a report issued on November 6, Cowen & Co. also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Based on Ultragenyx’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $87.31 million. In comparison, last year the company had a GAAP net loss of $79.23 million.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. Last month, Shalini Sharp, the CFO & EVP of RARE bought 12,000 shares for a total of $9,720.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.
